Gilead Sciences, Inc.

BMV:GILD * Stock Report

Market Cap: Mex$2.3t

Gilead Sciences Valuation

Is GILD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GILD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
Mex$3.61k
Fair Value
47.1% undervalued intrinsic discount
26
Number of Analysts

Below Fair Value: GILD * (MX$1910.62) is trading below our estimate of fair value (MX$3616.05)

Significantly Below Fair Value: GILD * is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GILD *?

Key metric: As GILD * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GILD *. This is calculated by dividing GILD *'s market cap by their current earnings.
What is GILD *'s PE Ratio?
PE Ratio20.2x
EarningsUS$5.97b
Market CapUS$120.55b

Price to Earnings Ratio vs Peers

How does GILD *'s PE Ratio compare to its peers?

The above table shows the PE ratio for GILD * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.4x
AMGN Amgen
24.1x12.02%US$143.0b
CSL CSL
26.6x13.00%AU$115.9b
REGN Regeneron Pharmaceuticals
12.4x7.55%US$55.8b
ABBV AbbVie
78.5x26.23%US$326.1b
GILD * Gilead Sciences
20.2x11.08%Mex$120.5b

Price-To-Earnings vs Peers: GILD * is good value based on its Price-To-Earnings Ratio (20.2x) compared to the peer average (35.5x).

Price to Earnings Ratio vs Industry

How does GILD *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

22 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies22PE020406080100+
22 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GILD * is good value based on its Price-To-Earnings Ratio (20.2x) compared to the Global Biotechs industry average (27.5x).

Price to Earnings Ratio vs Fair Ratio

What is GILD *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GILD * PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GILD *'s Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GILD * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentMex$1,910.62
Mex$2,255.42
+18.05%
11.71%Mex$2,744.83Mex$1,803.74n/a26
May ’26Mex$2,051.14
Mex$2,238.11
+9.12%
12.09%Mex$2,744.36Mex$1,803.44n/a26
Apr ’26Mex$2,274.05
Mex$2,268.24
-0.26%
13.93%Mex$2,842.69Mex$1,665.00n/a25
Mar ’26Mex$2,347.00
Mex$2,221.50
-5.35%
11.31%Mex$2,670.43Mex$1,684.43n/a27
Feb ’26Mex$1,960.00
Mex$2,075.03
+5.87%
12.95%Mex$2,576.69Mex$1,504.79n/a27
Jan ’26n/a
Mex$2,011.15
0%
12.62%Mex$2,541.31Mex$1,484.13n/a27
Dec ’25Mex$1,892.40
Mex$1,980.89
+4.68%
12.79%Mex$2,545.28Mex$1,404.99n/a28
Nov ’25Mex$1,785.69
Mex$1,757.90
-1.56%
13.89%Mex$2,458.84Mex$1,379.35n/a28
Oct ’25Mex$1,630.00
Mex$1,653.22
+1.42%
14.07%Mex$2,354.91Mex$1,355.56n/a27
Sep ’25n/a
Mex$1,638.53
0%
14.13%Mex$2,337.10Mex$1,345.31n/a27
Aug ’25Mex$1,341.67
Mex$1,498.86
+11.72%
15.06%Mex$2,162.83Mex$1,217.73n/a27
Jul ’25Mex$1,277.00
Mex$1,505.02
+17.86%
14.22%Mex$2,158.66Mex$1,215.38n/a26
Jun ’25n/a
Mex$1,403.02
0%
13.99%Mex$1,984.99Mex$1,136.70n/a26
May ’25Mex$1,121.00
Mex$1,424.27
+27.05%
12.99%Mex$1,991.08Mex$1,174.23Mex$2,051.1427
Apr ’25Mex$1,208.00
Mex$1,444.55
+19.58%
12.60%Mex$2,021.86Mex$1,152.96Mex$2,274.0526
Mar ’25Mex$1,228.00
Mex$1,497.82
+21.97%
12.55%Mex$2,062.81Mex$1,176.31Mex$2,347.0027
Feb ’25n/a
Mex$1,543.00
0%
11.88%Mex$1,989.49Mex$1,183.41Mex$1,960.0027
Jan ’25Mex$1,368.00
Mex$1,530.80
+11.90%
11.94%Mex$1,969.70Mex$1,171.63n/a27
Dec ’24n/a
Mex$1,564.57
0%
11.68%Mex$2,007.80Mex$1,228.91Mex$1,892.4027
Nov ’24Mex$1,430.00
Mex$1,622.48
+13.46%
11.16%Mex$2,069.44Mex$1,266.64Mex$1,785.6926
Oct ’24n/a
Mex$1,559.33
0%
10.82%Mex$1,980.51Mex$1,212.21Mex$1,630.0026
Sep ’24Mex$1,300.00
Mex$1,564.32
+20.33%
10.30%Mex$1,977.78Mex$1,363.98n/a24
Aug ’24Mex$1,273.18
Mex$1,542.18
+21.13%
10.14%Mex$1,935.30Mex$1,295.81Mex$1,341.6725
Jul ’24Mex$1,301.00
Mex$1,585.39
+21.86%
9.84%Mex$1,968.89Mex$1,318.30Mex$1,277.0025
Jun ’24Mex$1,346.00
Mex$1,631.83
+21.24%
9.81%Mex$2,026.86Mex$1,357.12n/a25
May ’24Mex$1,551.92
Mex$1,664.22
+7.24%
8.83%Mex$2,067.69Mex$1,438.39Mex$1,121.0025
AnalystConsensusTarget
Consensus Narrative from 26 Analysts
Mex$2.27k
Fair Value
15.8% undervalued intrinsic discount
26
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 08:51
End of Day Share Price 2025/05/08 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 69 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research